Jpmorgan Chase & CO Pharma Cyte Biotech, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 16 shares of PMCB stock, worth $15. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16
Previous 18
11.11%
Holding current value
$15
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding PMCB
# of Institutions
29Shares Held
682KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA194KShares$190,5580.0% of portfolio
-
Geode Capital Management, LLC Boston, MA127KShares$124,0700.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$90,2457.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$81,0720.09% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny49.8KShares$48,8040.0% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $20.3M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...